Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer

Exclusion Criteria

• •Malignant diseases other than pancreatic cancer diagnosed within 5 years before the first dose (excluding radically resected basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or radically resected carcinoma in situ)
• •Currently participating in interventional clinical research treatment, or having received other research drugs or used research devices within 4 weeks before the first dose
• •Active autoimmune disease
• •Allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation
• •Allergic to the active ingredients or excipients of this study drug, cadonilimab, S-1 or capecitabine
• •Have not fully recovered from any toxicity and/or complications caused by the intervention before starting treatment
• •History of HIV
• •Active HBV or HCV
• •Pregnant or breastfeeding women
• •Any severe or uncontrolled systemic disease
• •Active pulmonary tuberculosis
• •People with mental disorders who are unable to cooperate with treatment
• •Uncontrolled infection
• •The investigators assess that the subjects are unable to complete the entire trial process or are otherwise unsuitable for participating in this trial